New research underscores the possibility that interleukin (IL) 12, IL-23 or both play roles in the immunopathology of SLE. In the study, when added to standard-of-care treatment for active SLE, ustekinumab demonstrated better efficacy than placebo and had a safety profile consistent with that of ustekinumab therapy in other diseases…
On Nov. 1, after months of advocacy efforts spearheaded by the ACR and others, the Centers for Medicare and Medicaid Services (CMS) released the CY 2019 Medicare physician fee schedule rule, and it included several victories for rheumatology. Upon initial review, it appears the CMS has taken into account the concerns expressed by the ACR and…
In a long-term study, secukinumab proved safe and effective for treating ankylosing spondylitis…
Obesity is a modifiable risk factor for many patients with knee osteoarthritis (OA), and the National Institutes of Health recommend an initial weight loss goal of 10%. But how does losing more weight affect knee OA patients? In a new study, researchers compared the outcomes of knee OA patients who lost more and less than the recommended 10% of their baseline weight, finding significant improvement in health-related quality of life and reduction in pain for patients who lost twice what’s recommended…
It’s time to prepare for 2018 MIPS reporting via the Rheumatology Informatics System for Effectiveness (RISE) registry, and the ACR is here to help. To ensure you’re ready to submit your data to the CMS, RISE users should take the following steps: Complete the survey to notify the ACR of your intent to report via…
Both private and academic rheumatology practices face payer challenges that put the health of their patients and their practices at risk. To make sure the rheumatologist perspective is heard by payers, “the ACR’s Insurance Subcommittee (ISC) serves as the interface between payers and our members and ACR colleagues,” explains Sean Fahey, MD, a rheumatologist in…
Election Day 2018 has come and gone, and a new class of legislators will be joining the ranks of Congress in January. RheumPAC is the most important tool we have to establish relationships with our new legislators and this year, our ACR volunteer leaders stepped up and matched all donations to RheumPAC leading up to…
New research has provided a never-before-seen view of the genetic activity that may be used to map the polygenic nature of common rheumatic diseases. Two recent studies have employed distinct approaches to identify the non-coding gene variants, digging deep into human genetic data to uncover the mechanism of rheumatic diseases…
Mirtazapine has been prescribed off-label to fibromyalgia patients who have not responded to other treatments. However, a recent systemic review found no difference between mirtazapine and placebo for these patients, and any potential benefits from mirtazapine may not outweigh its potential harm, including drowsiness, weight gain and liver damage…
Late last month, the Centers for Medicare & Medicaid Services (CMS) released an advance notice of proposed rulemaking (ANPRM), seeking feedback on a potential drug pricing model called the International Pricing Index (IPI) model. This comment solicitation is in alignment with the administration’s blueprint to lower drug costs and reduce out-of-pocket costs, and is an…